Vor Biopharma (VOR) Interest Coverage Ratio (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Interest Coverage Ratio of 319.64 for Q1 2026, down 1520.7% year-over-year from 22.5 in Q1 2025, and up 2.22% quarter-over-quarter from 326.91 in Q4 2025.
Vor Biopharma (VOR) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Interest Coverage Ratio for 7 consecutive years, with 319.64 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 1520.7% year-over-year to 319.64; the TTM figure through Mar 2026 stood at 35.74 (down 94.84% YoY), while the FY2025 annual figure was 1.6, down 83.43% from the prior year.
- Interest Coverage Ratio advanced to 319.64 in Q1 2026 per VOR's latest filing, from 326.91 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 9.1 in Q4 2022 and bottomed at 780.75 in Q3 2025.
- Historically, Interest Coverage Ratio has averaged 132.41 across 5 years, with a median of 20.46 in 2022.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio slumped 47078.32% — and 2025, when it jumped 93.51%.
- Vor Biopharma's Interest Coverage Ratio stood at 9.1 in 2022, then declined by 29.04% to 11.74 in 2023, then slumped by 58.24% to 18.58 in 2024, then sank by 1659.26% to 326.91 in 2025, then rose by 2.22% to 319.64 in 2026.
- Business Quant data shows VOR's Interest Coverage Ratio at 319.64 in Q1 2026, 326.91 in Q4 2025, and 780.75 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | -51.90 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.90 |
| Mar 31, 2026 | -319.64 |
| Dec 31, 2025 | -326.91 |
| Sep 30, 2025 | -780.75 |
| Jun 30, 2025 | -26.90 |
| Mar 31, 2025 | -19.72 |
| Dec 31, 2024 | -18.58 |
| Sep 30, 2024 | -17.30 |
| Jun 30, 2024 | -414.79 |
| Mar 31, 2024 | -19.72 |
| Dec 31, 2023 | -11.74 |
| Sep 30, 2023 | -125.68 |
| Jun 30, 2023 | -72.14 |
| Mar 31, 2023 | -19.70 |
| Dec 31, 2022 | -9.10 |
| Sep 30, 2022 | -20.46 |
| Jun 30, 2022 | -16.43 |
| Mar 31, 2022 | -31.36 |
| Dec 31, 2021 | -25.46 |
| Sep 30, 2021 | -26.61 |